IL326224A - תצמידי נוגדנים וחלבוני איחוי - Google Patents

תצמידי נוגדנים וחלבוני איחוי

Info

Publication number
IL326224A
IL326224A IL326224A IL32622426A IL326224A IL 326224 A IL326224 A IL 326224A IL 326224 A IL326224 A IL 326224A IL 32622426 A IL32622426 A IL 32622426A IL 326224 A IL326224 A IL 326224A
Authority
IL
Israel
Prior art keywords
fusion proteins
antibody conjugates
conjugates
antibody
fusion
Prior art date
Application number
IL326224A
Other languages
English (en)
Original Assignee
Sixpeaks Bio Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sixpeaks Bio Ag filed Critical Sixpeaks Bio Ag
Publication of IL326224A publication Critical patent/IL326224A/he

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • C07K2317/524CH2 domain
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71Decreased effector function due to an Fc-modification
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
IL326224A 2023-07-31 2024-07-31 תצמידי נוגדנים וחלבוני איחוי IL326224A (he)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP23188568 2023-07-31
PCT/EP2024/071630 WO2025027052A1 (en) 2023-07-31 2024-07-31 Antibody conjugates and fusion proteins

Publications (1)

Publication Number Publication Date
IL326224A true IL326224A (he) 2026-03-01

Family

ID=87554544

Family Applications (1)

Application Number Title Priority Date Filing Date
IL326224A IL326224A (he) 2023-07-31 2024-07-31 תצמידי נוגדנים וחלבוני איחוי

Country Status (3)

Country Link
AU (1) AU2024317572A1 (he)
IL (1) IL326224A (he)
WO (1) WO2025027052A1 (he)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026037938A1 (en) * 2024-08-16 2026-02-19 Protuoso Pte. Ltd. Fusion proteins comprising a glp-1 receptor agonist and a myostatin pathway inhibitor

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
EP3263596A1 (en) 2002-12-16 2018-01-03 Genentech, Inc. Immunoglobulin variants and uses thereof
JP5766179B2 (ja) 2009-04-27 2015-08-19 ノバルティス アーゲー 筋肉増殖を増加させるための組成物および方法
HUE040276T2 (hu) * 2011-07-01 2019-02-28 Novartis Ag Eljárás metabolikus rendellenességek kezelésére
WO2013063536A1 (en) 2011-10-27 2013-05-02 Acceleron Pharma, Inc. Actriib binding agents and uses thereof
JP2015525230A (ja) 2012-06-11 2015-09-03 アムジエン・インコーポレーテツド デュアル受容体アンタゴニスト性抗原結合タンパク質およびその使用
WO2014172448A2 (en) 2013-04-17 2014-10-23 Anaptysbio, Inc. Antibodies directed against activin receptor type ii (actrii)
LT3129406T (lt) 2014-04-11 2019-04-10 Medimmune, Llc Konjuguoti junginiai, apimantys inžineriniu būdu sukonstruotus cisteino antikūnus
JP6987072B2 (ja) 2016-03-10 2021-12-22 アクセレロン ファーマ インコーポレーテッド アクチビン2型受容体結合タンパク質及びその使用
JOP20190152A1 (ar) 2016-12-21 2019-06-20 Novartis Ag مضادات الميوستاتين، الآكتيفين أو مستقبلات الآكتيفين للاستخدام في علاج السمنة والحالات ذات الصلة
AU2020284038A1 (en) 2019-05-30 2021-12-02 Acceleron Pharma Inc. ActRII-binding proteins and uses thereof
US20230220085A1 (en) 2020-02-28 2023-07-13 The Brigham And Women’S Hospital, Inc. Selective modulation of transforming growth factor beta superfamily signaling via multi-specific antibodies
GB2595299B (en) 2020-05-21 2022-08-03 Mabsolve Ltd Modified immunoglobulin FC regions
MX2023014840A (es) * 2021-06-23 2024-02-12 Scholar Rock Inc Un inhibidor de la vía de la miostatina en combinación con un activador de la vía de la glp-1 para su uso en el tratamiento de trastornos metabólicos.
JP2024532619A (ja) 2021-08-27 2024-09-05 バーサニス バイオ、インコーポレイテッド 併用療法
TW202339798A (zh) * 2022-01-19 2023-10-16 美商維紗妮絲生物公司 Actrii抗體之治療

Also Published As

Publication number Publication date
AU2024317572A1 (en) 2026-03-12
WO2025027052A1 (en) 2025-02-06

Similar Documents

Publication Publication Date Title
IL166632A (en) Antibody that binds an alpha-fetoprotein antigen and fusion protein comprising such
EP3758737A4 (en) IL-6 ANTIBODIES AND FUSION CONSTRUCTS AND CONJUGATES THEREOF
IL304190A (he) נוגדנים אנטי- pd-l1וחלבוני איחוי שלהם
IL306074A (he) נוגדני upar וחלבוני איחוי איתם
EP4417627A4 (en) Recombinant fusion antibody and antibody-drug conjugate and use thereof
EP3988576A4 (en) MONOCLONAL ANTIBODY CYTOKINE FUSION PROTEIN DIMER AND ITS USE
IL299238A (he) נוגדני anti-pd-1 וחלבונים מאוחים
IL310778A (he) נוגדנים sirp-אלפא ותצמידים
IL326224A (he) תצמידי נוגדנים וחלבוני איחוי
EP4126965A4 (en) ANTI-PD-L1 ANTIBODIES AND ANTI-PD-L1/IL10 FUSION PROTEINS
IL319054A (he) נוגדנים ומקטעי נוגדנים לאוריסטאטין מונומתיל
CA3262971A1 (en) NEW ANTI-NECTIN-4 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES
CA3300270A1 (en) Antibody conjugates and fusion proteins
IL319963A (he) נוגדנים, מצומדי נוגדן-תרופה, תכשירים ושימושים שלהם
EP4423260A4 (en) Truncated and fusion proteins
IL313553A (he) חלבונים מאוחים המכילים אנזימים אלפא-l-אידורונידאז ושיטות
EP4410841A4 (en) ANTI-IL23 ANTIBODY FUSION PROTEIN AND USES THEREOF
HK40110416A (en) Anti-il23 antibody fusion protein and uses thereof
HK40105570A (en) Antibody fusion proteins targeting il-6 receptor and angiogenic factors
EP4107190A4 (en) FUSION PROTEINS AND USES THEREOF
HK40104211A (en) GPC3-TARGETED ANTIBODY INTERFERON α FUSION PROTEIN AND USE THEREOF
IL326476A (he) מצמידי נוגדנים אנטי-cd203c והשימוש בהם
HK40104292A (en) Upar antibodies and fusion proteins with the same
IL313159A (he) נוגדני b7-h4 ונוגדן anti-b7-h4/חלבוני איחוי il-15
IL310247A (he) נוגדנים נקטין-4 ותצמידים